A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes
Status:
Terminated
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The primary objective is to demonstrate, after 52 weeks of treatment, the non-inferiority of
rimonabant 20 mg once daily (od) versus glimepiride od in reducing glycosylated haemoglobin
(HbA1c) in overweight/obese patients with type 2 diabetes not adequately controlled with
metformin at a stable dose (≥ 1500 mg/day) for at least 3 months.
The main secondary objectives are to assess the effect of rimonabant in comparison with
glimepiride on body weight and HDL-Cholesterol and the long-term safety and tolerability of
rimonabant in comparison with glimepiride.